GastroAGI Logo
OverviewBlogsAbout
Trending TopicsDaily BriefConference

Trending Topics in Gastroenterology

Explore current gastroenterology questions, clinical answers, and emerging research by topic.

101

Fibrates for Itch (FITCH) in Fibrosing Cholangiopathies

The FITCH trial investigated the efficacy of bezafibrate, a broad peroxisome proliferator-activated receptor (PPAR) agonist, in alleviating moderate to severe pruritus in patients with fibrosing cholangiopathies, including primary...

102

RESPONSE Trial and PBC

The RESPONSE trial was a pivotal phase 3 study designed to evaluate the efficacy and safety of seladelpar, a selective peroxisome proliferator–activated receptor delta (PPARδ) agonist, in patients...

103

ELATIVE and PBC

The ELATIVE trial was a clinical study designed to evaluate the efficacy and safety of elafibranor, a dual PPAR-α/δ agonist, as a potential second-line treatment for primary biliary...

104

POISE Study

The POISE study is a phase 3 clinical trial designed to evaluate the efficacy and safety of obeticholic acid (OCA), a farnesoid X receptor (FXR) agonist, in patients...

105

COBALT Trial and PBC

The COBALT Trial was a significant clinical study aimed at evaluating the long-term clinical benefits of obeticholic acid (OCA) in the treatment of primary biliary cholangitis (PBC), a...

106

Question Prompt List (QPL) for PBC

The Question Prompt List (QPL) for Primary Biliary Cholangitis (PBC) is a standardized tool designed to enhance physician-patient communication, improve patient engagement in care, and optimize health outcomes...

107

Risk Factors for Portal Vein Thrombosis in Liver Cirrhosis

Portal vein thrombosis (PVT) is a significant complication in patients with liver cirrhosis (LC), as it exacerbates portal hypertension and accelerates progression toward decompensation. Risk factors for PVT...

108

Prediction of the Risk of Developing Severe Liver Disease

The CORE model, developed by researchers at Karolinska Institutet, predicts the 10-year risk of developing severe liver diseases, such as cirrhosis and liver cancer, using a simple blood...

109

Antibiotics prophylaxis in GI bleeding in Cirrhosis Liver

Antibiotic Prophylaxis in Gastrointestinal (GI) Bleeding in Cirrhosis: A Comprehensive Overview Antibiotic prophylaxis has been a cornerstone in the management of cirrhotic patients with upper gastrointestinal (GI) bleeding...

110

Ultra-early (16 years) predictive model for MASLD

The ultra-early predictive model for Metabolic Dysfunction–Associated Steatotic Liver Disease (MASLD) is a promising development in preventive healthcare. This model relies on identifying specific protein changes in the...

Previous
1101112
Next
GastroAGI Logo

We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.

For You

For StudentsFor CliniciansFor ResearchersFor Patients

Core Tools

MELD-Na ScoreChild-PughFIB-4 IndexGlasgow-BlatchfordBISAP Score

Explore

OverviewAboutCalculators
Trending Topics
Conference Briefings
Blog Insights
©GastroAGI 2026
Privacy PolicyTerms of UseMedical Disclaimer